A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
European Journal of Cancer, 07/05/2012
Le Cesne A et al. – Trabectedin demonstrates encouraging disease control in translocation–related sarcoma (TRS). Since these promising results were generally noted in patients following chemotherapy, a phase III randomised trial in first–line is ongoing to compare trabectedin with doxorubicin–based chemotherapy in patients with TRS.